Country | ESR | SJC280–28 | TJC280–28 | LIM280–28 | MDGlobal0–10 | HAQ0–3 | MDHAQ0–3 | Pain0–10 | Global0–10 | Fatigue0–10 | DAS280–10 | %am15* |
Denmark | 14.0 | 1.0 | 2.0 | 0.0 | 1.3 | 0.63 | 0.50 | 2.6 | 2.8 | 3.6 | 3.3 | 56% |
Finland | 13.0 | 1.0 | 1.0 | 0.0 | 0.9 | 0.63 | 0.50 | 2.8 | 2.8 | 2.6 | 3.1 | 66% |
France | 16.0 | 1.0 | 2.0 | 1.0 | 2.5 | 0.88 | 0.60 | 3.9 | 3.6 | 4.2 | 3.6 | 60% |
Germany | 20.0 | 3.0 | 4.0 | 0.0 | 3.0 | 0.75 | 0.60 | 5.0 | 4.9 | 4.6 | 4.3 | 56% |
Ireland | 18.0 | 3.0 | 4.0 | 2.0 | 1.6 | 0.75 | 0.70 | 3.4 | 2.9 | 3.5 | 4.0 | 55% |
Italy | 28.0 | 2.0 | 4.0 | 0.0 | 3.0 | 1.06 | 0.80 | 4.9 | 5.0 | 4.9 | 4.5 | 51% |
The Netherlands | 15.0 | 1.0 | 0.0 | 1.0 | 0.6 | 0.75 | 0.60 | 2.5 | 2.7 | 3.1 | 3.0 | 49% |
Poland | 31.0 | 6.0 | 9.0 | 3.0 | 4.3 | 1.38 | 1.20 | 5.0 | 4.8 | 5.2 | 5.3 | 78% |
Spain | 17.0 | 1.0 | 1.0 | 0.0 | 1.2 | 0.88 | 0.72 | 3.2 | 3.6 | 3.7 | 3.5 | 47% |
Sweden | 19.0 | 2.0 | 2.0 | 1.0 | 1.3 | 0.88 | 0.70 | 3.3 | 3.3 | 3.7 | 3.6 | 67% |
UK | 21.0 | 1.0 | 4.0 | 0.0 | 2.0 | 0.88 | 0.70 | 4.2 | 3.8 | 5.1 | 4.2 | 65% |
Turkey | 30.0 | 0.0 | 2.5 | 0.0 | 2.0 | 0.88 | 0.70 | 4.2 | 4.6 | 4.5 | 4.1 | 53% |
Serbia | 28.0 | 6.0 | 18.0 | 2.0 | 4.6 | 1.63 | 1.40 | 5.1 | 5.3 | 5.5 | 6.1 | 71% |
USA | 14.0 | 2.0 | 1.0 | 0.0 | 1.9 | 0.63 | 0.56 | 3.3 | 2.6 | 3.2 | 3.2 | 58% |
Argentina | 30.0 | 9.0 | 10.5 | 2.0 | 4.6 | 1.00 | 0.90 | 5.0 | 4.7 | 6.3 | 5.6 | 64% |
Total | 21.0 | 2.0 | 3.0 | 1.0 | 2.2 | 0.88 | 0.70 | 4.0 | 4.0 | 4.4 | 4.0 | 61% |
DAS28, disease activity score on 28-joint count; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; LIM, limited motion/deformity joint count; MDGlobal, Doctor Global Assessment of Disease Activity; MDHAQ, multidimensional HAQ; QUEST-RA, Quantitative Patient Questionnaires in Standard Monitoring of Patients with Rheumatoid Arthritis; SJC, swollen joint count; TJC, tender joint count.
*Percentage of patients who report morning stiffness of 15 min or more.
A file including the interquartile ranges of variables is provided in the supplementary material.